{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:56:18Z","timestamp":1792007778679,"version":"4.4.0"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK","award":["209971"],"award-info":[{"award-number":["209971"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cholestatic pruritus is commonly reported in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC); however, information on pruritus in other chronic liver diseases (CLDs) is limited. This survey-based cohort study characterised the severity, persistence and impact of pruritus in PBC, PSC, chronic hepatitis B or C virus infection (HBV\/HCV), drug-induced liver injury, autoimmune hepatitis (AIH) and metabolic dysfunction-associated steatohepatitis (MASH). Here, we focus on groups that recruited the most participants: PSC, MASH and HCV. Results are presented in the context of PBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with a CLD of interest from the USA, the UK, Canada and Germany were screened for the presence of pruritus via the worst-itch numerical rating scale (WI-NRS, 3-month recall) between January 2021 and January 2022. Enrolled participants (single liver disease, non-transplant recipients) self-reporting pruritus with no extrahepatic causes in the past 3 months (WI-NRS\u22651) were eligible for further health-related quality-of-life (HRQoL) assessments, including WI-NRS (2-week recall), 5-dimensional itch scale and version two of the 36-Item Short-Form Health Survey. Questionnaires were administered at baseline (month 0), month 3 and month 6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 717 screened participants, 40.4% (AIH)\u201372.7% (HCV) reported any pruritus. Of 403 eligible participants, 357 were enrolled. Time since onset of pruritus to enrolment ranged from 28.0 (MASH) to 77.5 months (PBC). Baseline WI-NRS scores ranged from 3.8 (MASH) to 5.1 (PSC). The most selected terms used to describe pruritus across all CLDs were \u2018deep itch\u2019 and \u2018urgent itch\u2019 (range: 53.7% (HCV)\u201377.0% (PSC)). Participants with more severe pruritus had worse HRQoL. Intimate relationships, emotional well-being and ability to concentrate were negatively impacted by pruritus. Pruritus persisted over the 6-month study period across all CLDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study highlights the burden of pruritus experienced by participants across CLDs, highlighting a need to improve symptom recognition and treatments focused on improving HRQoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-001809","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:45:17Z","timestamp":1765453517000},"page":"e001809","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2040-1763","authenticated-orcid":false,"given":"Usha","family":"Gungabissoon","sequence":"first","affiliation":[{"name":"Global Epidemiology (Global Regulatory, Safety & Quality), GSK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2768-0272","authenticated-orcid":false,"given":"Jake","family":"Hunnicutt","sequence":"additional","affiliation":[{"name":"Epidemiology (Global Regulatory, Safety & Quality), GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-4171","authenticated-orcid":false,"given":"Eleanor J","family":"McDermott","sequence":"additional","affiliation":[{"name":"VEO Study Delivery, Global Clinical Operations, GSK, Stevenage, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-0673","authenticated-orcid":false,"given":"Andrew","family":"Lovley","sequence":"additional","affiliation":[{"name":"Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-9310","authenticated-orcid":false,"given":"Monica S","family":"Frazer","sequence":"additional","affiliation":[{"name":"Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-5822","authenticated-orcid":false,"given":"Kaitlin M","family":"LaGasse","sequence":"additional","affiliation":[{"name":"Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kosinski","sequence":"additional","affiliation":[{"name":"Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1046","authenticated-orcid":false,"given":"Kristen L","family":"McCausland","sequence":"additional","affiliation":[{"name":"Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-8837","authenticated-orcid":false,"given":"Ashleigh","family":"McGirr","sequence":"additional","affiliation":[{"name":"Epidemiology (Global Regulatory, Safety & Quality), GSK, Mississauga, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-5833","authenticated-orcid":false,"given":"Helen T","family":"Smith","sequence":"additional","affiliation":[{"name":"Value Evidence & Outcomes, GSK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M","family":"Hirschfield","sequence":"additional","affiliation":[{"name":"The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-8087","authenticated-orcid":false,"given":"Palak","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"National Institute for Health and Social Care Research (NIHR) Birmingham Biomedical Research Centre (BRC), Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, UK"},{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, UK"},{"name":"Institute of Applied Health Research, University of Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2025121103451248000_12.1.e001809.1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/hepr.13880","article-title":"Quality of life in Dutch patients with primary biliary cholangitis: Discrepancies between patients\u2019 perspectives and objective disease parameters","volume":"53","author":"de Veer","year":"2023","journal-title":"Hepatol Res"},{"key":"2025121103451248000_12.1.e001809.2","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)01040-1","article-title":"Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD)","volume":"78","author":"Dean","year":"2023","journal-title":"J Hepatol"},{"key":"2025121103451248000_12.1.e001809.3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121103451248000_12.1.e001809.4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2025121103451248000_12.1.e001809.5","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)01130-9","article-title":"THU-160 Long-term variability of pruritus in primary sclerosing cholangitis and implications for future clinical trial design","volume":"80","author":"Hussain","year":"2024","journal-title":"J Hepatol"},{"key":"2025121103451248000_12.1.e001809.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2023-001287","article-title":"Pruritus in primary biliary cholangitis is under-recorded in patient medical records","volume":"11","author":"Gungabissoon","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"2025121103451248000_12.1.e001809.7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-BASL.50"},{"key":"2025121103451248000_12.1.e001809.8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26365"},{"key":"2025121103451248000_12.1.e001809.9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2340\/00015555-0350","article-title":"Itch in primary biliary cirrhosis: a patients\u2019 perspective","volume":"88","author":"Rishe","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"2025121103451248000_12.1.e001809.10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i19.3418"},{"key":"2025121103451248000_12.1.e001809.11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/liv.12026","article-title":"Sleep-Wake profiles in patients with primary biliary cirrhosis","volume":"33","author":"Montagnese","year":"2013","journal-title":"Liver Int"},{"key":"2025121103451248000_12.1.e001809.12","unstructured":"PSC Support . Clinical need in PSC and clinically meaningful change: what is important to patients? 2016. Available: https:\/\/www.pscsupport.org.uk\/wp-content\/uploads\/2019\/06\/PSC-Support-Patient-Survey-Results.pdf [Accessed 15 Mar 2024]."},{"key":"2025121103451248000_12.1.e001809.13","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1016\/S0618-8278(19)30812-6","article-title":"FRI-062-Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patients\u2019 perspective","volume":"70","author":"Walmsley","year":"2019","journal-title":"J Hepatol"},{"key":"2025121103451248000_12.1.e001809.14","unstructured":"Gungabissoon U , Smith HT , von Maltzahn R , et al . Characterizing patients with pruritus and primary biliary cholangitis (PBC) in the PicnicHealthPBC cohort; contrasting medical record-documented pruritus with patient-reported pruritus from the PBC-40 (Poster No. 4748). AASLD 2022."},{"key":"2025121103451248000_12.1.e001809.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100931","article-title":"Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery","volume":"6","author":"Abbas","year":"2024","journal-title":"JHEP Rep"},{"key":"2025121103451248000_12.1.e001809.16","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8872804","article-title":"Rifampicin for Treatment of Cholestatic Pruritus Caused by Drug-Induced Acute Liver Injury as Assessed by the RUCAM Classification","volume":"2020","author":"Ahmadi","year":"2020","journal-title":"Case Reports Hepatol"},{"key":"2025121103451248000_12.1.e001809.17","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1111\/hepr.12978","article-title":"Prevalence of pruritus in patients with chronic liver disease: A multicenter study","volume":"48","author":"Oeda","year":"2018","journal-title":"Hepatol Res"},{"key":"2025121103451248000_12.1.e001809.18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol Commun"},{"key":"2025121103451248000_12.1.e001809.19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12325-018-0856-0","article-title":"Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study","volume":"36","author":"Cook","year":"2019","journal-title":"Adv Ther"},{"key":"2025121103451248000_12.1.e001809.20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.295"},{"key":"2025121103451248000_12.1.e001809.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-82566-w","article-title":"Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride","volume":"11","author":"Yoshikawa","year":"2021","journal-title":"Sci Rep"},{"key":"2025121103451248000_12.1.e001809.22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"2025121103451248000_12.1.e001809.23","unstructured":"Confirmit . Confirmit horizons v24. Norway, 2018."},{"key":"2025121103451248000_12.1.e001809.24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2340\/00015555-2642","article-title":"Tailoring the Cut-off Values of the Visual Analogue Scale and Numeric Rating Scale in Itch Assessment","volume":"97","author":"Reich","year":"2017","journal-title":"Acta Derm Venerol"},{"key":"2025121103451248000_12.1.e001809.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000857","article-title":"Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis","volume":"9","author":"Gungabissoon","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"2025121103451248000_12.1.e001809.26","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)00975-4","article-title":"THU-291 Clinical meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate-to-severe pruritus","volume":"82","author":"Levy","year":"2025","journal-title":"J Hepatol"},{"key":"2025121103451248000_12.1.e001809.27","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-021-00404-z","article-title":"Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus","volume":"5","author":"Vernon","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2025121103451248000_12.1.e001809.28","unstructured":"Maruish ME . User's manual for the SF-36v2 health survey: Quality Metric Incorporated. 2011."},{"key":"2025121103451248000_12.1.e001809.29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/liv.15803","article-title":"Persistent pruritus associated with worse quality of life in patients with chronic hepatitis","volume":"44","author":"Lu","year":"2024","journal-title":"Liver Int"},{"key":"2025121103451248000_12.1.e001809.30","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9625936","article-title":"Pruritus: Progress toward Pathogenesis and Treatment","volume":"2018","author":"Song","year":"2018","journal-title":"Biomed Res Int"},{"key":"2025121103451248000_12.1.e001809.31","unstructured":"Electronic Medicines Compendium . Questran light 4g\/sachet powder for oral suspension. 2022. Available: https:\/\/www.medicines.org.uk\/emc\/product\/10588\/smpc"},{"key":"2025121103451248000_12.1.e001809.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"2025121103451248000_12.1.e001809.33","unstructured":"FDA . Rifadin. 2010. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050420s073,050627s012lbl.pdf [Accessed 2024]."},{"key":"2025121103451248000_12.1.e001809.34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145"},{"key":"2025121103451248000_12.1.e001809.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13808-1"},{"key":"2025121103451248000_12.1.e001809.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1208814"},{"key":"2025121103451248000_12.1.e001809.37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-001809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:45:20Z","timestamp":1765453520000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-001809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjgast-2025-001809"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-001809","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}